Edesa Biotech Inc specializes in developing alternative treatments for inflammatory and immune-related diseases. Their product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. Additionally, the company is working on EB05, a monoclonal antibody therapy for hospitalized COVID-19 patients. Edesa Biotech Inc aims to provide effective solutions for these diseases while minimizing side effects.